SDZ 51641
SDZ 51641 is an orally active fatty acid oxidation inhibitor. By reducing fatty acid oxidation, SDZ 51641 deprives the gluconeogenesis process of required energy and cofactors, thereby lowering blood glucose levels in diabetic models. SDZ 51641 can be used in diabetes research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 91456-99-4
- 分子式: C14H20O2
- 分子量:220.31
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
SDZ 51641 (700 µmol/kg; p.o.; once daily; for 28 days) reduces body weight and testicular weight, while increases liver weight, in normal Sprague Dawley rats compared with the control group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague‑Dawley rats treated STZ[1]
-
Dosage:70 µmol/kg
-
Administration:p.o.; daily; 11 days
-
Result:Inhibited hepatic fatty acid oxidation, decreased β‑hydroxybutyrate levels, reduced blood glucose production, and lowered serum glucose levels, while avoiding toxic effects on peripheral tissues such as the testes.
化学情報
-
CAS 番号 91456-99-4
-
分子量 220.31
-
分子式 C14H20O2
-
SMILES
CC(C=C1)=CC=C1C2(C(C)(C)C)OCCO2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
- SDZ 51641
- 91456-99-4
- SDZ51641
- SDZ-51641
- Drug Intermediate
- long-chain acyl dehydrogenase
- fatty acid oxidation
- STZ-induced diabetic rats
- gluconeogenesis
- Sprague Dawley rats
- testicular toxicity
- carnitine palmitoyl transferase 2
- intramitochondrial CoA
- acetyl-CoA
- non-insulin-dependent diabetes mellitus
- Inhibitor
- inhibitor
- inhibit